Human papillomavirus (HPV) vaccines as an option for preventing cervical malignancies: (How) effective and safe?

Current Pharmaceutical Design

Volumn 19, Issue 8, 2013, Pages 1466-1487

  Tomljenovic, Lucija ^a   Spinosa, Jean Pierre ^b   Shaw, Christopher A ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Chargé de Cours   (Switzerland)

Author keywords

Adverse reactions; Cervarix; Conflict of interests; Gardasil; HPV vaccines; Vaccine efficacy; Vaccine safety

Indexed keywords

WART VIRUS VACCINE;

ACUTE DISSEMINATED ENCEPHALOMYELITIS; ANAPHYLAXIS; APPARENT LIFE THREATENING EVENT; AUTOIMMUNE DISEASE; CANCER MORTALITY; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC FATIGUE SYNDROME; CONVULSION; DEEP VEIN THROMBOSIS; DEMYELINATING DISEASE; DISABILITY; DRUG APPROVAL; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FACIAL NERVE PARALYSIS; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GUILLAIN BARRE SYNDROME; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; LUNG EMBOLISM; MULTIPLE SCLEROSIS; MYELITIS; PANCREATITIS; PAPANICOLAOU TEST; PARALYSIS; PARESTHESIA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SPONTANEOUS ABORTION; STUDY DESIGN; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UTERINE CERVIX CANCER; UTERINE CERVIX DYSPLASIA; VACCINATION; VISUAL IMPAIRMENT; WART VIRUS;

EID: 84876727382     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161213804805478     Document Type: Review

References (127)

1. WHO/ICO HPV Information Centre. Human papillomavirus and related cancers. Summary report update. November 15, 2010. Available at: http://apps.who.int/hpvcentre/statistics/dynamic/ico/ country_pdf/XWX.pdf?CFID=5169709&CFTOKEN=39667351 [Accessed 21 July 2011].
2. Tomljenovic L, Shaw CA. Human papillomavirus (HPV) vaccine policy and evidence-based medicine: Are they at odds? Ann Med 2011. [Epub ahead of print].
3. Castle PE. Beyond human papillomavirus: the cervix, exogenous secondary factors, and the development of cervical precancer and cancer. J Low Genit Tract Dis 2004; 8(3): 224-30.
4. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003; 88(1): 63-73.
5. Clifford GM, Gallus S, Herrero R, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 2005; 366(9490): 991-8.
6. Australian Government Department of Health and Ageing. Screening to prevent cervical cancer: guidelines for the management of asymptomatic women with screen detected abnormalities, NHMRC, National Screening Program. 2005. Available at: http://www.nhmrc.gov.au/_files_nhmrc/file/publications/synopses/ wh39.pdf [Accessed 28 March 2011].
7. Harper DM, Vierthaler SL. Next Generation Cancer Protection: The Bivalent HPV Vaccine for Females. ISRN Obstet Gynecol 2011; 2011: 457204.
8. Schlecht NF, Platt RW, Duarte-Franco E, et al. Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. J Natl Cancer Inst 2003; 95(17): 1336-43.
9. U.S. Food and Drug Administration (FDA) News Release. June 8, 2006. FDA Licenses New Vaccine for Prevention of Cervical Cancer and Other Diseases in Females Caused by Human Papillomavirus. Rapid Approval Marks Major Advancement in Public Health. Available at: http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ 2006/ucm108666.htm [Accessed 19 March 2012].
10. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56(RR-2): 1-24.
11. Cancer Council Australia. Cervical Cancer Vaccine. Available at: http://www.cervicalcancervaccine.org.au/ [Accessed 19 March 2012].
12. Centers for Disease Control and Prevention (CDC). FDA Licensure of Bivalent Human Papillomavirus Vaccine (HPV2, Cervarix) for Use in Females and Updated HPV Vaccination Recommendations from the Advisory Committee on Immunization Practices (ACIP). Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/ mm5920a4.htm [Accessed 19 March 2012].
13. Harper DM, Williams KB. Prophylactic HPV vaccines: current knowledge of impact on gynecologic premalignancies. Discov Med 2010; 10(50): 7-17.
14. Garland SM, Hernandez-Avila M, Wheeler CM, et al. (FUTURE) I Investigators) Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356(19): 1928-43.
15. Wiley DJ, Douglas J, Beutner K, et al. External genital warts: diagnosis, treatment, and prevention. Clin Infect Dis 2002; 35(Suppl 2): S210-24.
16. McGee G, Johnson S. Has the spread of HPV vaccine marketing conveyed immunity to common sense? Am J Bioeth 2007; 7(7): 1-2.
17. Flogging gardasil. Nat Biotechnol 2007; 25(3): 261.
18. Rothman SM, Rothman DJ. Marketing HPV vaccine: implications for adolescent health and medical professionalism. JAMA 2009; 302(7): 781-6.
19. Mello MM, Abiola S, Colgrove J. Pharmaceutical Companies' Role in State Vaccination Policymaking: The Case of Human Papillomavirus Vaccination. Am J Public Health 2012; 102(5): 893-8.
20. Haug C. The risks and benefits of HPV vaccination. JAMA 2009; 302(7): 795-6.
21. WHO/ICO. Information Centre on Human Papilloma Virus and Cervical Cancer. Available at: http://apps.who.int/hpvcentre/statistics/dynamic/ico/SummaryRepo rtsSelect.cfm [Accessed 21 July 2011].
22. de Kok IM, van Ballegooijen M, Habbema JD. Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands. J Natl Cancer Inst 2009; 101(15): 1083-92.
23. Kulasingam SL, Benard S, Barnabas RV, Largeron N, Myers ER. Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: A cost-effectiveness analysis. Cost Eff Resour Alloc 2008; 6: 4.
24. Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. N Engl J Med 2008; 359(8): 821-32.
25. Annemans L, Remy V, Oyee J, Largeron N. Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium. Pharmacoeconomics 2009; 27(3): 231-45.
26. Gerhardus A, Razum O. A long story made too short: surrogate variables and the communication of HPV vaccine trial results. J Epidemiol Community Health 2010 May; 64(5): 377-8.
27. Kristensen FB, Gerhardus A. Health technology assessments: what do differing conclusions tell us? BMJ 2010; 341: c5236.
28. Merck Newsroom. U.S. Prescribing Information for GARDASIL® Updated; Indication Not Granted for Use in Adult Women, April 6, 2011. Available at: http://www.merck.com/newsroom/newsrelease-archive/vaccine-news/2011_0406.html Accessed 19 March 2012].
29. Lippman A, Melnychuk R, Shimmin C, Boscoe M. Human papillomavirus, vaccines and women's health: questions and cautions. CMAJ 2007; 177(5): 484-7.
30. Spinosa JP, Riva C, Biollaz J. Letter to the editor response to the article of Luisa Lina Villa HPV prophylactic vaccination: the first years and what to expect from now. Cancer Lett 2011; 304(1): 70.
31. Tomljenovic L, Shaw CA. Mandatory HPV vaccination. JAMA 2012; 307(3): 254; author reply-5.
32. Sarojini NB, Srinivasan S, Madhavi Y, Srinivasan S, Shenoi A. The HPV Vaccine: Science, Ethics and Regulation. Econ Polit Weekly 2010; 45(48): 27-34.
33. The Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356(19): 1915-27.
34. Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374(9686): 301-14.
35. Harper DM, Nieminen P, Paavonen J, Lehtinen M. Cervical cancer incidence can increase despite HPV vaccination. Lancet Infect Dis 2010; 10(9): 594-5; author reply 5.
36. De Carvalho N, Teixeira J, Roteli-Martins CM, et al. Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women. Vaccine 2010; 28(38): 6247-55.
37. Romanowski B, de Borba PC, Naud PS, et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebocontrolled trial up to 6.4 years. Lancet 2009; 374(9706): 1975-85.
38. U.S. Food and Drug Administration. Fast Track, Accelerated Approval and Priority Review. Available at: http://www.fda.gov/ forconsumers/ byaudience/forpatientadvocates/speedingaccesstoimportantnewt herapies/ucm128291.htm [Accessed 19 March 2012].
39. McCredie MR, Sharples KJ, Paul C, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol 2008; 9(5): 425-34.
40. de Sanjose S, Diaz M, Castellsague X, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007; 7(7): 453-9.
41. Kitchener HC, Almonte M, Thomson C, et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol 2009; 10(7): 672-82.
42. Bruni L, Diaz M, Castellsague X, Ferrer E, Bosch FX, de Sanjose S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 2010; 202(12): 1789-99.
43. Eversole GM, Moriarty AT, Schwartz MR, et al. Practices of participants in the college of american pathologists interlaboratory comparison program in cervicovaginal cytology, 2006. Arch Pathol Lab Med 2010; 134(3): 331-5.
44. Franco EL, Villa LL, Sobrinho JP, et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 1999; 180(5): 1415-23.
45. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998; 338(7): 423-8.
46. Moscicki AB, Shiboski S, Broering J, et al. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr 1998; 132(2): 277-84.
47. Molano M, Van den Brule A, Plummer M, et al. Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am J Epidemiol 2003; 158(5): 486-94.
48. Schiffman M, Rodriguez AC. Heterogeneity in CIN3 diagnosis. Lancet Oncol 2008; 9(5): 404-6.
49. Castle PE, Schiffman M, Wheeler CM, Wentzensen N, Gravitt PE. Impact of improved classification on the association of human papillomavirus with cervical precancer. Am J Epidemiol 2009; 171(2): 155-63.
50. Castle PE, Stoler MH, Solomon D, Schiffman M. The relationship of community biopsy-diagnosed cervical intraepithelial neoplasia grade 2 to the quality control pathology-reviewed diagnoses: an ALTS report. Am J Clin Pathol 2007; 127(5): 805-15.
51. Carreon JD, Sherman ME, Guillén D, et al. CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological review of populationbased cervical samples. International J Gynecol Pathol 2007; 26(4): 441-6.
52. Moscicki AB, Ma Y, Wibbelsman C, et al. Rate of and risks for regression of cervical intraepithelial neoplasia 2 in adolescents and young women. Obstet Gynecol 2010; 116(6): 1373-80.
53. Ostor AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol 1993; 12(2): 186-92.
54. Food and Drug Administration Vaccines and Related Biological Products Advisory Committee (VRBPAC) Background Document: Gardasil™ HPV Quadrivalent Vaccine. May 18, 2006 VRBPAC Meeting. Available at: http://www.fda.gov/ohrms/dockets/ ac/06/briefing/2006-4222B3.pdf [Accessed 19 March 2012].
55. Villa LL, Costa RL, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006; 95(11): 1459-66.
56. Merck&Co. Protection with Gardasil. Available at: http://www.gardasil.com/what-is-gardasil/cervical-cancervaccine/ index.html [Accessed 20 July 2011].
57. American Academy of Pediatrics (AAP) statement on HPV vaccine. Press release, September 13, 2011. Available at: http://www.immunizeadultga.org/pdfs/aap_hpv2011.pdf [Accessed 19 March 2012].
58. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364(9447): 1757-65.
59. Paper provided by MHRA for Joint Committee on Vaccination and Immunisation June 2010: Vaccine associated suspected adverse reactions reported via the Yellow Card scheme during 2009. Available from: http://www.dh.gov.uk/prod_consum_dh/groups/ dh_digitalassets/@dh/@ab/documents/digitalasset/dh_118753.pdf [Accessed 17 July 2011].
60. U.S. Centers for Disease Control and Prevention (CDC). Information from FDA and CDC on Gardasil and its Safety (Archived). 2008. Available at: http://www.cdc.gov/vaccinesafety/ Vaccines/ HPV/HPVArchived.html [Accessed 22 July 2011].
61. Irish Medicines Board (IMB). Update on national monitoring experience with Gardasil. 11th November 2010. Available at: http://www.imb.ie/images/uploaded/documents/IMB_Gardasil_We bUpdate_11Nov2010.pdf [Accessed 17 July 2011].
62. Food and Drug Administration. Workshop on Non-clinical Safety Evaluation of Preventative Vaccines: Recent Advances and Regu latory Considerations. 2002. Available at: http://www.fda.gov/ downloads/biologicsbloodvaccines/newsevents/workshopsmeeting sconferences/transcriptsminutes/ucm054459.pdf [Accessed 30 May 2011].
63. Diaz M, Kim JJ, Albero G, et al. Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India. Br J Cancer 2008; 99(2): 230-8.
64. Slade BA, Leidel L, Vellozzi C, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 2009; 302(7): 750-7.
65. Paper provided by MHRA for Joint Committee on Vaccination and Immunisation June 2009: Vaccine associated suspected adverse reactions reported via the Yellow Card scheme during 2008. Available at: http://www.dh.gov.uk/prod_consum_dh/groups/ dh_digitalassets/@dh/@ab/documents/digitalasset/dh_110017.pdf [Accessed 17 July 2011].
66. Database of the Netherlands Pharmacovigilance Centre Lareb. Overview adverse events following immunization in association with Cervarix. February 3, 2010. Available at: http://www.lareb.nl/documents/kwb_2010_2_cerva.pdf [Accessed 24 July 2011].
67. Irish Medicines Board (IMB). Update on national monitoring experience with Gardasil. 9th February 2011. Available at: http://www.imb.ie/images/uploaded/documents/IMB_Gardasil_We bUpdate_09Feb2011.pdf [Accessed 17 July 2011].
68. Lawrence G, Gold MS, Hill R, Deeks S, Glasswell A, McIntyre PB. Annual report: Surveillance of adverse events following immunisation in Australia, 2007. Commun Dis Intell 2008; 32(4).
69. Menzies R, Mahajan D, Gold MS, Roomiani I, McIntyre P, Lawrence G. Annual report: Surveillance of adverse events following immunisation in Australia, 2008. Commun Dis Intell 2009; 33(4).
70. Mahajan D, Roomiani I, Gold MS, Lawrence GL, McIntyre PB, Menzies RI. Annual report: Surveillance of adverse events following immunisation in Australia, 2009. Comm Dis Intell 2010; 34(3).
71. Agence Francaise de Securite Sanitaire des Produits de Sante (AFSSAPS). Vaccins contre les infections dûes à certains papillomavirus humains (HPV). Gardasil®: Troisième bilan du plan de gestion des risques européen et national (12/07/2011). Available at: http://www.afssaps.fr/Dossiers-thematiques/Vaccins/Vaccinscontre-les-infections-dues-a-certains-papillomavirus-humains-HPV/%28offset%29/2 [Accessed 17 July 2011].
72. U.S. Centers for Disease Control and Prevention (CDC). WONDER VAERS Request. Available at: http://wonder.cdc.gov/vaers.html [Accessed March 2012]
73. Souayah N, Michas-Martin PA, Nasar A, et al. Guillain-Barre syndrome after Gardasil vaccination: data from Vaccine Adverse Event Reporting System 2006-2009. Vaccine 2011; 29(5): 886-9.
74. Chustecka Z. HPV Vaccine: Debate Over Benefits, Marketing, and New Adverse Event Data. Medscape Med News. 2009. Available at: http://www.medscape.com/viewarticle/707634 [Accessed 25 January 2011].
75. Suspected adverse reactions received by the MHRA. Cervarix Human papillomavirus (HPV) vaccine (as of 29 July 2010). Available at: http://www.mhra.gov.uk/PrintPreview/DefaultSplashPP/ CON023340?ResultCount=10&DynamicListQuery=&DynamicLis tSortBy=xCreationDate&DynamicListSortOrder=Desc&Dynamic ListTitle=&PageNumber=1&Title=Human%20papillomavirus% 20%28HPV%29%20vaccine [Accessed 24 July 2011].
76. Della Corte C, Carlucci A, Francalanci P, Alisi A, Nobili V. Autoimmune hepatitis type 2 following anti-papillomavirus vaccination in a 11-year-old girl. Vaccine. 2011; 29(29-30): 4654-6.
77. Soldevilla HF, Briones SF, Navarra SV. Systemic lupus erythematosus following HPV immunization or infection? Lupus 2012; 21(2): 158-61.
78. Sutton I, Lahoria R, Tan IL, Clouston P, Barnett MH. CNS demyelination and quadrivalent HPV vaccination. Multiple Sclerosis 2009; 15: 116-9.
79. Chang J, Campagnolo D, Vollmer TL, Bomprezzi R. Demyelinating disease and polyvalent human papilloma virus vaccination. J Neurol Neurosurg Psychiatry 2010; 82(11): 1296-8.
80. Alvarez-Soria MJ, Hernandez-Gonzalez A, Carrasco-Garcia de Leon S, Del Real-Francia MA, Gallardo-Alcaniz MJ, Lopez-Gomez JL. [Demyelinating disease and vaccination of the human papillomavirus.]. Rev Neurol 2011; 52(8): 472-6.
81. Mendoza Plasencia Z, Gonzalez Lopez M, Fernandez Sanfiel ML, Muniz Montes JR. [Acute disseminated encephalomyelitis with tumefactive lesions after vaccination against human papillomavirus]. Neurologia 2010; 25(1): 58-9.
82. Wildemann B, Jarius S, Hartmann M, Regula JU, Hametner C. Acute disseminated encephalomyelitis following vaccination against human papilloma virus. Neurology 2009; 72(24): 2132-3.
83. Schaffer V, Wimmer S, Rotaru I, Topakian R, Haring HP, Aichner FT. HPV vaccine: a cornerstone of female health a possible cause of ADEM? J Neurol 2008; 255(11): 1818-20.
84. McCarthy JE, Filiano J. Opsoclonus Myoclonus after human papilloma virus vaccine in a pediatric patient. Parkinsonism Relat Disord 2009; 15(10): 792-4.
85. Debeer P, De Munter P, Bruyninckx F, Devlieger R. Brachial plexus neuritis following HPV vaccination. Vaccine 2008; 26(35): 4417-9.
86. Cohen SM. Multiple Evanescent White Dot Syndrome After Vaccination for Human Papilloma Virus and Meningococcus. J Pediatr Ophthalmol Strabismus 2009: 1-3.
87. Das A, Chang D, Biankin AV, Merrett ND. Pancreatitis following human papillomavirus vaccination. Med J Aust 2008; 189(3): 178.
88. Brotherton JM, Gold MS, Kemp AS, McIntyre PB, Burgess MA, Campbell-Lloyd S. Anaphylaxis following quadrivalent human papillomavirus vaccination. CMAJ 2008; 179(6): 525-33.
89. Blitshteyn S. Postural tachycardia syndrome after vaccination with Gardasil (letter to the editor). Eur J Neurol 2010; 17(7): e52.
90. Gandey A. Report of Motor Neuron Disease After HPV Vaccine. Medscape Med News. 2009. Available at: http://www.medscape. com/viewarticle/711461 [Accessed 25 January 2011].
91. Löwer J. Two unclear cases of death. Can we still recommend HPV vaccination? MMW Fortschr Med 2008; 150(8): 6.
92. Merck&Co. Gardasil product sheet. Date of Approval 2006. Available at: http://www.fda.gov/downloads/BiologicsBloodVaccines/ Vaccines/ApprovedProducts/UCM111263.pdf [Accessed 25 July 2011].
93. Shoenfeld Y, Agmon-Levin N. 'ASIA'-Autoimmune/ inflammatory syndrome induced by adjuvants. J Autoimmun 2011; 36(1): 4-8.
94. Couette M, Boisse MF, Maison P, et al. Long-term persistence of vaccine-derived aluminum hydroxide is associated with chronic cognitive dysfunction. J Inorg Biochem 2009; 103(11): 1571-8.
95. Authier FJ, Cherin P, Creange A, et al. Central nervous system disease in patients with macrophagic myofasciitis. Brain 2001; 124(Pt 5): 974-83.
96. Exley C, Swarbrick L, Gherardi RK, Authier FJ. A role for the body burden of aluminium in vaccine-associated macrophagic myofasciitis and chronic fatigue syndrome. Med Hypotheses 2009; 72(2): 135-9.
97. Gherardi RK, Coquet M, Cherin P, et al. Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminium hydroxide in muscle. Brain 2001; 124(Pt 9): 1821-31.
98. Shaw CA, Petrik MS. Aluminum hydroxide injections lead to motor deficits and motor neuron degeneration. J Inorg Biochem 2009; 103(11): 1555-62.
99. Petrik MS, Wong MC, Tabata RC, Garry RF, Shaw CA. Aluminum adjuvant linked to Gulf War illness induces motor neuron death in mice. Neuromolecular Med 2007; 9(1): 83-100.
100. Tomljenovic L, Shaw CA. Do aluminum vaccine adjuvants contribute to the rising prevalence of autism? J Inorg Biochem 2011; 105(11): 1489-99.
101. Tomljenovic L, Shaw CA. Aluminum Vaccine Adjuvants: Are they Safe? Curr Med Chem 2011; 18(17): 2630-7.
102. Tomljenovic L, Shaw CA. Mechanisms of aluminum adjuvant toxicity in pediatric populations. Lupus 2012; 21(2): 223-30.
103. Verstraeten T, Descamps D, David MP, et al. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine 2008; 26(51): 6630-8.
104. Israeli E, Agmon-Levin N, Blank M, Shoenfeld Y. Adjuvants and autoimmunity. Lupus 2009; 18(13): 1217-25.
105. Cohen AD, Shoenfeld Y. Vaccine-induced autoimmunity. J Autoimmun 1996; 9(6): 699-703.
106. Agmon-Levin N, Paz Z, Israeli E, Shoenfeld Y. Vaccines and autoimmunity. Nat Rev Rheumatol 2009; 5(11): 648-52.
107. Chao C, Klein NP, Velicer CM, et al. Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. J Intern Med 2011; 271(2): 193-203.
108. Krumholz HM, Ross JS, Presler AH, Egilman DS. What have we learnt from Vioxx? BMJ 2007; 334(7585): 120-3.
109. Carragee EJ, Hurwitz EL, Weiner BK. A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J 2011; 11(6): 471-91.
110. Angell M. Industry-sponsored clinical research: a broken system. JAMA 2008; 300(9): 1069-71.
111. DeAngelis CD, Fontanarosa PB. Impugning the integrity of medical science: the adverse effects of industry influence. JAMA 2008; 299(15): 1833-5.
112. Engeland A, Haldorsen T, Tretli S, et al. Prediction of cancer mortality in the Nordic countries up to the years 2000 and 2010, on the basis of relative survival analysis. A collaborative study of the five Nordic Cancer Registries. APMIS Suppl 1995; 49: 1-161.
113. Laukkanen P, Koskela P, Pukkala E, et al. Time trends in incidence and prevalence of human papillomavirus type 6, 11 and 16 infections in Finland. J Gen Virol 2003; 84(Pt 8): 2105-9.
114. Fagot JP, Boutrelle A, Ricordeau P, Weill A, Allemand H. HPV vaccination in France: uptake, costs and issues for the National Health Insurance. Vaccine 2011; 29(19): 3610-6.
115. Berkhof J, Bogaards J, Couṕe V, Meijer CJM. Modelling the influence of screening uptake on the future incidence of cervical cancer and the cost-effectiveness of HPV vaccination. In: Proceedings of the 26th International Papillomavirus Conference, Montreal, Canada, July 2010.
116. Lancucki L, Fender M, Koukari A, et al. A fall-off in cervical screening coverage of younger women in developed countries. J Med Screen 2010; 17(2): 91-6.
117. Reynales-Shigematsu LM, Rodrigues ER, Lazcano-Ponce E. Costeffectiveness analysis of a quadrivalent human papilloma virus vaccine in Mexico. Arch Med Res 2009; 40(6): 503-13.
118. Haverkos H. Multifactorial Etiology of Cervical Cancer: A Hypothesis. Medscape General Med 2005; 7(4): 57.
119. World Health Organization International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, volume 64, Human Papillomaviruses. 1995. Available at: http://monographs.iarc.fr/ENG/Monographs/vol64/ volume64.pdf [Accessed 28 March 2011].
120. Castle PE, Giuliano AR. Chapter 4: Genital tract infections, cervical inflammation, and antioxidant nutrients-assessing their roles as human papillomavirus cofactors. J Natl Cancer Inst Monogr 2003; 31: 29-34.
121. Sorensen HT, Friis S, Norgard B, et al. Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. Br J Cancer. 2003; 88(11): 1687-92.
122. Szarewski A, Maddox P, Royston P, et al. The effect of stopping smoking on cervical Langerhans' cells and lymphocytes. BJOG 2001; 108(3): 295-303.
123. Smith JS, Green J, Berrington de Gonzalez A, et al. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet 2003; 361(9364): 1159-67.
124. Frazer I. God's gift to women: the human papillomavirus vaccine. Immunity 2006; 25(2): 179-84.
125. Tomljenovic L, Shaw CA. Too Fast or Not Too Fast: The FDA's Approval of Merck's HPV Vaccine Gardasil. J Law Med Ethics 2012; 40(3): 673-81.
126. Brisson M, Van de Velde N, De Wals P, Boily MC. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine 2007; 25(29): 5399-408.
127. Sharma M, Ortendahl J, van der Ham E, Sy S, Kim J. Costeffectiveness of human papillomavirus vaccination and cervical cancer screening in Thailand. BJOG 2011; 119(2): 166-76.